Shah Capital Management Has Upped Its Vimpelcom LTD Spon (VIP) Stake; Synbiotics Has 0.67 Sentiment

August 3, 2017 - By Clifton Ray

About 301 shares traded or Infinity% up from the average. ALPS Medical Breakthroughs ETF (SBIO) has risen 9.19% since August 3, 2016 and is uptrending. It has underperformed by 7.51% the S&P500.

Shah Capital Management increased Vimpelcom Ltd Spon (VIP) stake by 32.68% reported in 2016Q4 SEC filing. Shah Capital Management acquired 778,725 shares as Vimpelcom Ltd Spon (VIP)’s stock 0.00%. The Shah Capital Management holds 3.16 million shares with $12.17M value, up from 2.38 million last quarter. Vimpelcom Ltd Spon now has $7.47 billion valuation. The stock rose 2.95% or $0.12 reaching $4.19 per share. About 3.24 million shares traded or 1.25% up from the average. VEON Ltd (ADR) (NASDAQ:VIP) has 0.00% since August 3, 2016 and is . It has underperformed by 16.70% the S&P500.

Kcg Holdings Inc. holds 0.01% of its portfolio in ALPS Medical Breakthroughs ETF for 14,295 shares. Raymond James & Associates owns 145,822 shares or 0.01% of their US portfolio. Moreover, Ameriprise Financial Inc has 0% invested in the company for 9,868 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Citadel Advisors Llc, a Illinois-based fund reported 64,035 shares.

Among 7 analysts covering VimpelCom (NASDAQ:VIP), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. VimpelCom had 15 analyst reports since August 7, 2015 according to SRatingsIntel. As per Wednesday, September 14, the company rating was upgraded by Renaissance Capital. The stock of VEON Ltd (ADR) (NASDAQ:VEON) has “Equal Weight” rating given on Wednesday, August 26 by Barclays Capital. The company was upgraded on Tuesday, November 10 by Citigroup. Barclays Capital maintained it with “Equal Weight” rating and $4.82 target in Friday, November 27 report. The rating was maintained by Goldman Sachs with “Buy” on Tuesday, February 14. As per Friday, April 8, the company rating was downgraded by Citigroup. The stock of VEON Ltd (ADR) (NASDAQ:VEON) earned “Hold” rating by HSBC on Tuesday, August 11. On Monday, August 10 the stock rating was upgraded by Deutsche Bank to “Hold”. The stock of VEON Ltd (ADR) (NASDAQ:VEON) has “Outperform” rating given on Friday, August 7 by RBC Capital Markets. On Monday, November 9 the stock rating was maintained by RBC Capital Markets with “Outperform”.